Does clozapine (Clozaril) cause tachycardia?

Does Clozapine Cause Tachycardia?

Yes, clozapine causes tachycardia in approximately 68% of patients, making it one of the most common adverse effects of this medication. 1

Incidence and Clinical Course

Tachycardia is extremely common with clozapine treatment:

• 68% of patients develop tachycardia during treatment 1
• 93.5% of patients experience at least one heart rate >100 bpm during the first month 2
• 68% meet criteria for persistent tachycardia (three consecutive days with HR >100 bpm) 2
• 35.8% experience heart rates >120 bpm at some point during titration 2

The tachycardia typically:

• Occurs early during clozapine titration, often within the first weeks 1, 2
• Shows a dose-response relationship at lower doses (plateaus between 150-350 mg daily) 2
• May be transient in some patients but persists in approximately 44% at day 28 2
• Can spontaneously resolve without intervention in a subset of patients 2

Mechanism

Clozapine-induced tachycardia results from:

• Direct blockade of cardiac muscarinic M2 receptors
• Blockade of presynaptic α2 adrenoceptors
• Indirect activation of β adrenoceptors
• Overall sympathetic nervous system activation 3

Monitoring Recommendations

Heart rate should be routinely monitored throughout clozapine treatment 1. The 2026 Lancet Psychiatry consensus guidelines specifically recommend:

• Regular heart rate monitoring during titration
• Continued monitoring as part of routine adverse drug reaction screening
• Watchful monitoring may be appropriate before initiating rate-controlling medications, given spontaneous resolution in some patients 2

Management Algorithm

For Transient Tachycardia:

• Slow titration of clozapine can mitigate risk 1
• Watchful waiting is reasonable if tachycardia is mild and patient is asymptomatic 2

For Persistent Tachycardia:

Persistent tachycardia should be managed with:

1. Beta blockers (atenolol or bisoprolol) as first-line 1
2. Ivabradine as an alternative rate-controlling agent 1
3. Dose reduction with adjunctive antipsychotic (e.g., lurasidone) if tachycardia persists despite beta blockers 3

Risk Factors:

• Female sex is associated with early tachycardia at day 14 (though not at day 28) 2
• Concurrent valproic acid increases rates of tachycardia (45.7% vs 17.8% in monotherapy) 4
• Age, smoking status, and BMI are not significantly associated with tachycardia risk 2

Critical Pitfalls

Do not confuse tachycardia with QT prolongation. Recent evidence shows that apparent clozapine-induced QT prolongation is largely an artifact of tachycardia and over-correction by Bazett's formula 5. When using heart rate-independent correction methods (Fredericia, Hodges, or QT nomogram), only 0.3% of patients showed true QT prolongation versus 27.5% with Bazett's formula 5.

Do not automatically discontinue clozapine for tachycardia alone. Given clozapine's unique efficacy in treatment-resistant schizophrenia, tachycardia should be managed with rate-controlling medications or dose adjustments rather than premature discontinuation 3.

Monitor for myocarditis separately. While tachycardia is common and often benign, it can also be an early warning sign of clozapine-induced cardiac inflammation (myocarditis), which typically occurs in the first months after initiation 1. Tachycardia accompanied by chest pain, fever, or elevated inflammatory markers warrants immediate cardiac evaluation 6.